AIM ImmunoTech vs Vyome
AIM and HIND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIM and HIND compare
Vyome is the larger company, worth 2.4 times as much as AIM ImmunoTech ($11.0M against $4.5M).
AIM ImmunoTech grew revenue faster over the last twelve months (−21.5% versus −67.1% for Vyome).
Vyome keeps more of each dollar of sales as profit, with a net margin of −8717% compared with −15021% at AIM ImmunoTech.
AIM ImmunoTech scores higher on the StockData Score (2 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIM | HIND |
|---|---|---|
| Size and price | ||
| Market cap | $4.5M | $11.0M |
| Share price | $0.148 | $1.57 |
| Change, 1 year | −90.6% | −71.1% |
| Change, 5 years | −99.9% | −100.0% |
| Beta (5Y) | 0.84 | 1.56 |
| Employees | – | 18 |
| StockData Score | ||
| Total score | 2 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 47.6× (better) | 84.9× |
| P/B | 0.6× | – |
| Growth | ||
| Revenue growth (TTM) | −21.5% (better) | −67.1% |
| Revenue growth, 5Y average | −11.6% (better) | −51.0% |
| Profitability | ||
| Gross margin | – | 52.7% |
| Operating margin | −11724% | −9190% (better) |
| Net margin | −15021% | −8717% (better) |
| Return on equity | −2382% | −194% (better) |
| Return on invested capital | – | −173% |
| Financial health | ||
| Debt / equity | 0.47 | – |
| Interest coverage | −9.8× (better) | −285.8× |
| Current ratio | 2.11 | 4.37 (better) |
| Altman Z-score | −51.04 | −13.52 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 38.9% |
| Shareholder yield | 0.00% | 38.9% (better) |
| Ownership | ||
| Held by institutions | 3.8% | 2.0% |
| Held by insiders | 12.8% | 6.8% |
| Insider net buying, 12 months | $33.9K | – |
| Short interest, % of float | 3.8% | 0.28% |
Go deeper
- AIM stock overview
- AIM income statement
- AIM valuation and score
- HIND stock overview
- HIND income statement
- HIND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.